Name: Developing New Treatments for T Cell Lymphoma
Uploaded: 2011-12-27
Duration: 5 min
Description: Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and brentuximab vedotin.

Important Update to Visitor Policy. Please read important information about COVID-19 vaccination requirements or testing for some visitors. Read our visitor policy.

Sloan Kettering Institute
Research
- - Changing how the world understands and treats cancer
    Our scientists pursue every aspect of cancer research—from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more.
- - Programs & Centers
  - Sloan Kettering Institute
    Pursuing basic and translational research across 9 programs and 100+ labs
  - Memorial Hospital research
    Focusing on clinical cancer research and population health
  - Human Oncology & Pathogenesis Program (HOPP)
    Bridging the lab and the clinic through translational research
  - Collaborative research centers
    Fostering interdisciplinary collaborations between laboratory scientists and clinicians
  - Extramural collaborations
    Partnering with other academic and research institutions
- - Research at MSK
  - Our research impact
  - Research topics
  - Core facilities & resources
    Offering state-of-the-art resources for our researchers
  - Find a researcher or lab
  - Education & training programs
Education & Training
- - Training the next generation of clinicians and scientists
    Our highly-specialized educational programs shape leaders to be at the forefront of cancer care and research.
- - For Research
  - Postdoctoral training
  - Gerstner Sloan Kettering Graduate School of Biomedical Sciences
    Offering a curriculum with a focus on cancer
  - PhD & MD/PhD programs
  - MSK Bridge program
    Connecting college seniors to future careers in biomedicine
  - High school & undergraduate summer programs
Careers
MSK Direct
- - In the U.S.
  - English
  - Español
  - Pу́сский
  - Outside of the U.S.
  - العَرَبِيَّة
  - Deutsch
  - English
  - Español
  - 한국어
  - עִבְרִית
  - Italiano
  - Português
  - Pу́сский
  - Türkçe
  - 中文

Make an Appointment
- - We’re here for you.
    Make an appointment
    New patient
    Current patient
    Speak to a care advisor
    Adults: 833-920-3234
    Monday to Friday, 9 a.m. to 5 p.m. (Eastern time)
    Children & Teens: 833-MSK-KIDS
    Monday to Friday, 9 a.m. to 5 p.m. (Eastern time)
- - Becoming A Patient
  - How to get started
  - Insurance & financial assistance
  - Preparing for your first appointment
  - Meet our doctors
  - Explore our locations
Refer a Patient
- - Partner with us to treat your patient’s cancer.
    Refer a patient
    Call Physician Access Team
    833-340-1151
    Monday to Friday, 9 a.m. to 5 p.m. (Eastern time)
- - Clinical Resources
  - Our doctors
  - Physician relations
  - Clinical updates & insights
  - Prediction tools
  - Clinical trials
  - Continuing medical education (CME)
Learn About Cancer & Treatment
- - We treat every type of cancer, including the most important one: yours.
    With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need, when you need it.
- - Adults
  - Cancers & conditions
  - Risk assessment & screening
  - Diagnosis & treatment
  - Clinical trials
  - Children & Teens
  - Cancers & conditions
  - Diagnosis & treatment
  - Clinical trials
- - Support, Services & Programs
  - For adults
  - For children & teens
  - For caregivers
  - Adolescents & young adult (AYA) program
  - Patient & caregiver education library
  - Cancer News & Discoveries
  - Read the latest
  - Sign up for our newsletter
About Us
- - We’re always leading the fight against cancer.
    Memorial Sloan Kettering was founded in 1884, and today is a world leader in patient care, research, and educational programs.
- - About Us
  - Leadership
  - History
  - Equality, diversity & inclusion
  - Annual report
  - Give to MSK
  - For the Media
  - Media inquiries
  - News releases
  - News & information
- - Have Questions?
  - Contact us
  - Plan Your Visit
  - Explore our locations
  - Directions
  - Visitor policy
Patient Portal: MyMSK
Donate Now
- Sloan Kettering Institute
- Research
  - - Programs & Centers
    - Sloan Kettering Institute
      Pursuing basic and translational research across 9 programs and 100+ labs
    - Memorial Hospital research
      Focusing on clinical cancer research and population health
    - Human Oncology & Pathogenesis Program (HOPP)
      Bridging the lab and the clinic through translational research
    - Collaborative research centers
      Fostering interdisciplinary collaborations between laboratory scientists and clinicians
    - Extramural collaborations
      Partnering with other academic and research institutions
  - - Research at MSK
    - Our research impact
    - Research topics
    - Core facilities & resources
      Offering state-of-the-art resources for our researchers
    - Find a researcher or lab
    - Education & training programs
- Education & Training
  - - For Research
    - Postdoctoral training
    - Gerstner Sloan Kettering Graduate School of Biomedical Sciences
      Offering a curriculum with a focus on cancer
    - PhD & MD/PhD programs
    - MSK Bridge program
      Connecting college seniors to future careers in biomedicine
    - High school & undergraduate summer programs
- Careers
- MSK Direct
- - - In the U.S.
    - English
    - Español
    - Pу́сский
    - Outside of the U.S.
    - العَرَبِيَّة
    - Deutsch
    - English
    - Español
    - 한국어
    - עִבְרִית
    - Italiano
    - Português
    - Pу́сский
    - Türkçe
    - 中文

VIDEO | 05:00

Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and brentuximab vedotin.

Changing how the world understands and treats cancer

Training the next generation of clinicians and scientists